BioLineRx Ltd (BLRX)

[midastouch017]

Short Interest in BioLineRx Ltd.
(BLRX) Expands By 49.6%

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 804,376 shares, an increase of 49.6% from the July 31st total of 537,795 shares. Based on an average daily trading volume, of 843,299 shares, the short-interest ratio is currently 1.0 days.
Several research firms recently issued reports on BLRX. Maxim Group set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Tuesday, August 8th. Roth Capital set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx in a report on Friday, August 4th. They issued an “outperform” rating and a $3.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $2.59.

https://ledgergazette.com/2017/08/31/short-interest-in-biolinerx-ltd-blrx-expands-by-49-6.html

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC raised its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC acquired a new stake in BioLineRx during the first quarter worth $126,000. Benchmark Capital Advisors raised its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC acquired a new stake in BioLineRx during the first quarter worth $3,018,000. Hedge funds and other institutional investors own 32.27% of the company’s stock.